Cargando…

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients

OBJECTIVES: To identify the best experimental approach to detect a SARS-CoV-2-specific T cell response using a whole-blood platform. METHODS: Whole-blood from 56 COVID-19 and 23 “NO-COVID-19” individuals were stimulated overnight with different concentrations (0.1 or 1 μg/mL) of SARS-CoV-2 PepTivato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aiello, Alessandra, Najafi Fard, Saeid, Petruccioli, Elisa, Petrone, Linda, Vanini, Valentina, Farroni, Chiara, Cuzzi, Gilda, Navarra, Assunta, Gualano, Gina, Mosti, Silvia, Pierelli, Luca, Nicastri, Emanuele, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045417/ https://www.ncbi.nlm.nih.gov/pubmed/33864921 http://dx.doi.org/10.1016/j.ijid.2021.04.034

Ejemplares similares

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
por: Najafi-Fard, Saeid, et al.
Publicado: (2023)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
por: Aiello, Alessandra, et al.
Publicado: (2023)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses
por: Najafi Fard, Saeid, et al.
Publicado: (2021)

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
por: Petruccioli, Elisa, et al.
Publicado: (2018)

Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy
por: Gualano, Gina, et al.
Publicado: (2019)

Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood
por: Chiacchio, Teresa, et al.
Publicado: (2011)

Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy
por: Musso, Maria, et al.
Publicado: (2021)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry
por: Alonzi, Tonino, et al.
Publicado: (2019)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
por: Farroni, Chiara, et al.
Publicado: (2022)

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
por: Cantini, Fabrizio, et al.
Publicado: (2020)

IP-10 detection in urine is associated with lung diseases
por: Cannas, Angela, et al.
Publicado: (2010)

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
por: Chiacchio, Teresa, et al.
Publicado: (2017)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis
por: Musso, Maria, et al.
Publicado: (2019)

Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts
por: Petrone, Linda, et al.
Publicado: (2021)

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
por: Agrati, Chiara, et al.
Publicado: (2022)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023)

Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts
por: Petrone, Linda, et al.
Publicado: (2015)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
por: Alonzi, Tonino, et al.
Publicado: (2021)

Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis
por: Batisti Biffignandi, Gherard, et al.
Publicado: (2023)

Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art
por: Minardi, Maria Letizia, et al.
Publicado: (2021)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2023)

Tuberculosis Biomarkers: From Diagnosis to Protection
por: Goletti, Delia, et al.
Publicado: (2016)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Methylated HBHA Produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders
por: Delogu, Giovanni, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_d2raqc3cnin02vfidk94m5o6v6